Edwards Lifesciences executive Daniel Lippis exercised Options covering 619 shares at $72.68 each and sold 619 shares at $87.51 each on September 11, 2026. The transactions left him with 40,034 shares and 3,714 derivative securities, while the exercise represented about 14.3% of his prior derivative-securities holding.
Key Highlights
- Daniel Lippis held 40,034 Edwards Lifesciences shares after selling 619 shares at $87.51 each.
- The option exercise left Lippis with 3,714 derivative securities.
- The 619 derivative securities exercised represented about 14.3% of his prior derivative-securities holding.
Edwards Lifesciences Corp (NYSE: EW) executive Daniel Lippis exercised options covering 619 shares at $72.68 per share on September 11, 2026. He also sold 619 shares at $87.51 per share on the same date.
Option Exercise And Share Sale
The exercise left him with 40,653 shares of Edwards Lifesciences. Transaction code S identified the sale, after which his shareholding stood at 40,034 shares. The exercise and sale each involved 619 shares. The sale price was $87.51 per share, compared with the $72.68 exercise price.
Derivative Securities And Resulting Holdings
The option exercise also covered 619 derivative securities and left Lippis with 3,714 derivative securities. That transaction represented about 14.3% of his prior derivative-securities holding. The 619-share exercise represented about 1.5% of his resulting shareholding of 40,653 shares. The 619-share sale represented about 1.5% of his prior shareholding.
FAQs
Q: What did the Edwards Lifesciences insider transaction involve?
A: Daniel Lippis exercised options covering 619 Edwards Lifesciences shares at $72.68 each. He also sold 619 shares at $87.51 each on September 11, 2026.
Q: How many Edwards Lifesciences shares did Daniel Lippis own afterward?
A: Lippis held 40,034 Edwards Lifesciences shares after the sale. His holding was 40,653 shares after the option exercise, before the separate share sale.
Q: What happened to Lippis’s derivative securities?
A: The option exercise left Daniel Lippis with 3,714 Edwards Lifesciences derivative securities. The transaction represented about 14.3% of his prior derivative-securities holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.